Mesenchymal Stem Cells: The First Approved Stem Cell Drug in Japan

Najima, Yuho; Ohashi, Kazuteru

doi:10.7889/hct-16-031

Cited by 14 publications

(6 citation statements)

References 52 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunologic rejection is a main drawback of allogeneic-based cell therapy [ 43 ]. Based on their immunomodulatory effects, MSCs are applied for graft-versus-host disease therapy in some countries [ 44 , 45 ]. Even for allogenic MSCs, however, immunologic rejection has been reported [ 44 ].…”

Section: Basic Characteristics Of Muse Cellsmentioning

confidence: 99%

Non-Tumorigenic Pluripotent Reparative Muse Cells Provide a New Therapeutic Approach for Neurologic Diseases

Yamashita

Kushida

Abe

et al. 2021

Cells

View full text Add to dashboard Cite

Muse cells are non-tumorigenic endogenous reparative pluripotent cells with high therapeutic potential. They are identified as cells positive for the pluripotent surface marker SSEA-3 in the bone marrow, peripheral blood, and connective tissue. Muse cells also express other pluripotent stem cell markers, are able to differentiate into cells representative of all three germ layers, self-renew from a single cell, and are stress tolerant. They express receptors for sphingosine-1-phosphate (S1P), which is actively produced by damaged cells, allowing circulating cells to selectively home to damaged tissue. Muse cells spontaneously differentiate on-site into multiple tissue-constituent cells with few errors and replace damaged/apoptotic cells with functional cells, thereby contributing to tissue repair. Intravenous injection of exogenous Muse cells to increase the number of circulating Muse cells enhances their reparative activity. Muse cells also have a specific immunomodulatory system, represented by HLA-G expression, allowing them to be directly administered without HLA-matching or immunosuppressant treatment. Owing to these unique characteristics, clinical trials using intravenously administered donor-Muse cells have been conducted for myocardial infarction, stroke, epidermolysis bullosa, spinal cord injury, perinatal hypoxic ischemic encephalopathy, and amyotrophic lateral sclerosis. Muse cells have the potential to break through the limitations of current cell therapies for neurologic diseases, including amyotrophic lateral sclerosis. Muse cells provide a new therapeutic strategy that requires no HLA-matching or immunosuppressant treatment for administering donor-derived cells, no gene introduction or differentiation induction for cell preparation, and no surgery for delivering the cells to patients.

show abstract

Section: Basic Characteristics Of Muse Cellsmentioning

confidence: 99%

Non-Tumorigenic Pluripotent Reparative Muse Cells Provide a New Therapeutic Approach for Neurologic Diseases

Yamashita

Kushida

Abe

et al. 2021

Cells

View full text Add to dashboard Cite

show abstract

“…Also in that year, umbilical cord blood-derived MSCs (UC-MSCs) were used in South Korea to treat knee osteoarthritis (Cartistem)[ 30 ]. Recently, the Japanese government has approved HS Temcell, which contains allogeneic MSCs from bone marrow for GVHD treatment[ 31 , 32 ]. In Europe, adipose-derived MSCs have been approved for Crohn’s disease[ 33 ].…”

Section: How Mesenchymal Stem Cells Can Be Used In Covid-19 Treatmentmentioning

confidence: 99%

Off-the-shelf mesenchymal stem cells from human umbilical cord tissue can significantly improve symptoms in COVID-19 patients: An analysis of evidential relations

Pham

2020

WJSC

View full text Add to dashboard Cite

Coronavirus disease-2019 (COVID-19) has affected more than 200 countries worldwide. This disease has hugely affected healthcare systems as well as the economy to an extent never seen before. To date, COVID-19 infection has led to about 165000 deaths in 150 countries. At present, there is no specific drug or efficient treatment for this disease. In this analysis based on evidential relationships of the biological characteristics of MSCs, especially umbilical cord (UC)-derived MSCs as well as the first clinical trial using MSCs for COVID-19 treatment, we discuss the use of UC-MSCs to improve the symptoms of COVID-19 in patients.

show abstract

“…Human mesenchymal stem cells (MSCs) have been investigated as a promising cell source for regenerative medicine due to their self‐renewability, multipotency, immunosuppression, and the absence of ethical concerns 1 . MSCs are widely used in preclinical and clinical regenerative medicine including the treatment of acute graft versus host diseases, 2 type I diabetes mellitus, 3 and chronic liver disease 4 . Recently, COVID‐19 treatment options using MSCs and MSC‐derived exosomes, extracellular vesicles of ~100 nm average size, and their therapeutic potential with paracrine activities 5 have been investigated 6 .…”

Section: Introductionmentioning

confidence: 99%

Image‐based hybrid model incorporating initial spatial distribution for mesenchymal stem cell cultivation process design

Hirono,

Hayashi,

A. Udugama

et al. 2024

AIChE Journal

View full text Add to dashboard Cite

This work presents an image‐based hybrid model incorporating the initial spatial distribution for mesenchymal stem cell (MSC) cultivation process design. First, three levels of seeding bias in static MSC cultivation were experimentally investigated, and the resulting initial distribution was quantified using phase contrast microscopy image analysis. Second, the observed spatial heterogeneity was defined as a new parameter by calculating the standard deviation of the seeded cell number fraction among numerical 8 × 8 tiles on two‐dimensional plates. Third, the parameter was incorporated into kinetic models to consider spatial growth limitation. The model was then applied to simulate MSC cultivation processes with experimental data. Using dynamic and stochastic simulation outputs, feasible ranges of cell‐harvesting time could be determined to satisfy a given requirement for the minimum cell number and acceptable confluency level. The developed hybrid model could serve as a basis for quantitative decision‐making in the design of MSC cultivation processes.

show abstract

Mesenchymal Stem Cells: The First Approved Stem Cell Drug in Japan

Abstract: 125 IntroductionVarious advances in the care of patients undergoing HSCT have improved the outcomes following transplantation.1 Nev- Characteristics of MSCsThe definition of MSCs has three minimum require-

Cited by 14 publications

References 52 publications

Non-Tumorigenic Pluripotent Reparative Muse Cells Provide a New Therapeutic Approach for Neurologic Diseases

Non-Tumorigenic Pluripotent Reparative Muse Cells Provide a New Therapeutic Approach for Neurologic Diseases

Off-the-shelf mesenchymal stem cells from human umbilical cord tissue can significantly improve symptoms in COVID-19 patients: An analysis of evidential relations

Image‐based hybrid model incorporating initial spatial distribution for mesenchymal stem cell cultivation process design

Contact Info

Product

Resources

About